echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: Hormone replacement therapy increases the risk of breast cancer in BRCA mutation carriers over 45 years old by 3 times!

    Eur J Cancer: Hormone replacement therapy increases the risk of breast cancer in BRCA mutation carriers over 45 years old by 3 times!

    • Last Update: 2021-03-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BRCA1/BRCA2 mutation carriers usually undergo salpingo-oophorectomy (RRSO) before natural menopause to reduce the risk of ovarian cancer and fallopian tube cancer, but this increases the use of hormone replacement therapy (HRT) problems.

    Ovarian cancer

    There is conflicting evidence regarding the impact of hormone replacement therapy on breast cancer (BC) risk; in addition, there are limited risk data based on age of exposure.
    In the general population, HRT users have an increased risk of breast cancer (hazard ratio [HR]=1.
    34)
    .

    Breast cancer In the general population, HRT users have an increased risk of breast cancer (hazard ratio [HR]=1.
    34).
    In the general population, HRT users have an increased risk of breast cancer (hazard ratio [HR]=1.
    34)

    This study aims to assess the impact of short-term use of HRT on the risk of breast cancer in healthy people with BRCA1/2 mutations, focusing on the age at the time of HRT exposure.

    The impact of short-term use of HRT on the risk of breast cancer in healthy people with BRCA1/2 mutations focuses on the age at the time of exposure to HRT.

    The researchers conducted a retrospective cohort follow-up of 306 healthy people with BRCA1/2 mutations who received RRSO, with an average follow-up of 7.
    26 years.
    The incidence of breast cancer in carriers with or without HRT was compared over time.

    Breast cancer incidence after RRSO

    Breast cancer incidence after RRSO

    During follow-up, 36 carriers were diagnosed with breast cancer: 20 out of 148 carriers in the HRT group were diagnosed as breast cancer (13.
    5%), and 16 out of 155 carriers in the non-HRT group (10.
    3%) (advantage Ratio [OR]=1.
    4, 95%CI 0.
    7-2.
    7).

    During follow-up, 36 carriers were diagnosed with breast cancer: 20 out of 148 carriers in the HRT group were diagnosed as breast cancer (13.
    5%), and 16 out of 155 carriers in the non-HRT group (10.
    3%) (advantage Ratio [OR]=1.
    4, 95%CI 0.
    7-2.
    7).
    diagnosis

    Among women ≤45 years of age undergoing RRSO, HRT exposure does not affect the incidence of breast cancer.
    However,
    among people who underwent RRSO after the age of 45, the prevalence of breast cancer among HRT users was significantly higher than that of non-HRT users (OR=3.
    43, P<0.
    05, 95%CI 1.
    2-9.
    8)
    .

    Among the population undergoing RRSO after the age of 45, the prevalence of breast cancer among HRT users was significantly higher than that of non-HRT users (OR=3.
    43, P<0.
    05, 95%CI 1.
    2-9.
    8)

    In summary, among BRCA1/BRCA2 mutation carriers, women over 45 years of age who use hormone replacement therapy short-term after salpingo-oophorectomy have a three-fold increase in breast cancer risk .
    The results of this study show that the relationship between hormone replacement therapy and breast cancer risk is related to the age of HRT exposure, even among BRCA1/2 carriers.

    Among BRCA1/BRCA2 mutation carriers, women over 45 years of age who use hormone replacement therapy for short-term after salpingo-oophorectomy have an increased risk of breast cancer by up to 3 times as much as 3 times

    Original source:

    Original source:

    Michaelson-Cohen Rachel, Gabizon-Peretz Shira, Armon Shunit et al.
    Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy .
    Eur J Cancer, 2021, 148: 95-102.

    Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.